Genmab — December 2024
-
Uanset hvad vil jeg også gerne sige tusind tak EL for de mange informationer om Genmab. Som Solsen lige skrev, så er blot den sidste artikel jo monster interessant. Og der er sikkert andre end mig, der læser alle dine links, selv om vi er godt trætte af at vente på hexen...
-
I videoen her gennemgår vi Genmab med 3-PointPlaybook-strategien. Her kigger vi på følgende punkter:
- Er aktien solid?
- Er aktien godt prissat?
- Er timingen rigtig? https://proinvestor.com/boards/123320
-
Japanese acasunlimab safety trial Completed https://clinicaltrials.gov/study/NCT04937153?tab=history&a=17&b=18&compareMode=sideBySide#version-content-panel
-
https://x.com/Larvol/status/1864673303862157521/photo/1 promising #ClinicalTrials, most discussed among the oncologists on X - TRIMM-2 = Talq-Dara, Epcore= Epco, MajesTEC=Teclistamab, Auriga & AQUILA =Dara
-
Danmark har flere store virksomheder, som danskerne er stolte af, og som er blevet til folkeaktier. Men det seneste års tid har der været udfordringer, som har fået nogle danskere til at søge grønnere græsgange. Lyt med, når Helge Larsen kigger på udfordringerne hos to af folkeaktierne - nemlig Vestas og Genmab. https://proinvestor.com/boards/123323
-
Teknisk analyse på Genmab https://proinvestor.com/boards/123349
-
En fair value, der er til at forstå
https://simplywall.st/stocks/dk/pharmaceuticals-biotech/cph-gmab/genmab-shares -
@Bulder hehe, synes dog tit at Simplty har værdiansættelser helt hen i vejret.
Kigger man på forudsætningerne fra beregningen antager beregningen en FCF på nuværende 6 mia som vokser til underkanten af 20 mia i 2030, og fortsætter i samme tempo. Er dette en realistisk projektion? Hmm 
-
Jeg bliver altid så glad, når jeg læser dine indlæg Riis. Det minder mig om, at Proinvestor har plads til alle.
-
Genmab
@Genmab
We are presenting new clinical data at #ASH24 across subtypes of non-Hodgkin’s lymphoma (#NHL), a type of cancer that affects the lymphatic system, usually found in the lymph nodes. Swipe to learn more about this disease and how it can affect patients.
https://x.com/Genmab/status/1865097213652668441 -
-
Investigational Epcoritamab (DuoBody
CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL). https://ir.genmab.com/news-releases/news-release-details/investigational-epcoritamab-duobodyr-cd3xcd20-combination https://ir.genmab.com/news-releases/news-release-details/investigational-epcoritamab-duobodyr-cd3xcd20-combination -
-
slides-
Fernando Martín Moro
@Fer_martinmoro
Fixed-Duration Epcoritamab + R2 in R/R Follicular Lymphoma: 2-Year Follow-up from Arm 2 Epcore NHL-2 Trial https://x.com/Fer_martinmoro/status/1865569927740203505 -
The Fixed duration regime is offcourse a response to glofitamab competition- this poster suggests it may be better to keep treating to progression (for some patients?)
https://x.com/DrRaulCordoba/status/1865654728618852709 @DrRaulCordoba
#ASH24 Interesting study
: “Treatment to progression vs FDT efficacy of #epcoritamab: a modeling and simulation study”
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind